Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
AKAP12
REST API REST API
Homo sapiens
AKAP12 is differentially expressed in 321 experiments: 137 organism parts: liver, testis, ... (135 more);, 236 disease states: normal, lung adenocarcinoma, ... (234 more);, 108 cell types 532 cell lines 43 compound treatments and 78 other conditions.
Synonyms AKAP250, SSeCKS
Orthologs YFR016C (Saccharomyces cerevisiae)   AKAP12 (Gallus gallus)   Akap12 (Rattus norvegicus)   Akap12 (Mus musculus)   AKAP12 (2 of 2) (Danio rerio)   akap12b (Danio rerio)   akap12 (Xenopus laevis)   AKAP12 (Bos taurus)   AKAP12 (Canis familiaris)   Msp-300 (Drosophila melanogaster)   (Compare orthologs)
Gene Ontology Term plasma membrane, cytoskeleton, cytoplasm, cell cortex, protein targeting, G-protein coupled receptor protein signaling pathway, protein kinase A binding, signal transduction, positive regulation of cAMP biosynthetic process, positive regulation of protein kinase A signaling cascade, adenylate cyclase binding
InterPro Term Pkinase-A_anch_WSK-motif, RII_binding_1
UniProt Accession Q02952
Search EB-eye ENSG00000131016
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (45 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
SW480
3
E-MTAB-37, E-MEXP-1014, E-GEOD-2509
Jurkat
2
E-GEOD-1880, E-MTAB-62
LNCaP
2
E-GEOD-14464, E-GEOD-14990
AGS
2
E-GEOD-15460, E-MTAB-37
BT474
2
E-MTAB-37, E-MTAB-62
526 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-22529, E-GEOD-20193, E-MEXP-1121, E-GEOD-21668, ... (48 experiments)

Factor Value U/D Experiments
2
E-TABM-130, E-TABM-145
neutrophil
2
E-GEOD-12662, E-GEOD-3982
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
fibroblast
1
2
E-GEOD-3920, E-GEOD-3204, E-MEXP-466
macrophage
1
2
E-MEXP-1290, E-GEOD-360, E-GEOD-3982
endothelial cell
1
2
E-GEOD-96, E-GEOD-19240, E-GEOD-3920
102 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1028, E-GEOD-15960, E-GEOD-1577, E-TABM-15, ... (65 experiments)

Factor Value U/D Experiments
chronic lymphocytic leukemia
2
E-MTAB-37, E-GEOD-6691
obesity
2
E-MTAB-62, E-GEOD-2508
T-cell acute lymphoblastic leukemia
2
E-MTAB-37, E-GEOD-1577
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
gastric carcinoma
2
E-GEOD-15460, E-MTAB-37
230 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-GEOD-697, E-GEOD-5824, E-GEOD-7708, ... (25 experiments)

Factor Value U/D Experiments
none
2
11
E-GEOD-5741, E-MEXP-1958, E-MEXP-1269, E-GEOD-7708, E-GEOD-412, ... (13 experiments)
dihydrotestoterone
1
E-GEOD-7708
granulocyte-colony stimulating factor
1
E-GEOD-7400
BCR/FGFR1
1
1
E-GEOD-15811
ultrafine particles
1
E-GEOD-4567
TNF
1
E-GEOD-15205
37 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-4619, ... (7 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-2509, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-2466, E-GEOD-17476, E-GEOD-3624, E-GEOD-22593, ... (16 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, E-TABM-440, E-MEXP-1273, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-5764, E-GEOD-1028, E-GEOD-1926, ... (28 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-9723, E-GEOD-6927, E-MEXP-561, E-GEOD-923 ... (5 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-923, E-GEOD-7114, ... (6 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-1422, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-12293, E-GEOD-19069, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-19246, E-GEOD-19136, E-GEOD-13818, E-GEOD-19815, E-GEOD-15799 ... (5 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-4922

Processing time: 0.294 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM